Avastin Unsuccessful as Adjuvant Therapy in Setting of Stage II and III Colon Cancer but May Be Effective if Given for Longe... ( Cancer resea...)

HOME >> MEDICINE >> NEWS

Avastin Unsuccessful as Adjuvant Therapy in Setting of Stage II and III Colon Cancer but May Be Effective if Given for Longer Duration

Date:5/30/2009

Cancer researchers from the National Surgical Adjuvant Breast and Bowel Project (NSABP) and Allegheny General Hospital (AGH) in Pittsburgh reported today at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando that use of the drug bevacizumab (Avastin) in combination with standard chemotherapy was not effective in prolonging disease-free survival (DFS) among patients with stage II and stage III colon cancer when given for one year. There is promise that using Avastin for periods longer than one year will lead to improved efficacy.

Pittsburgh, PA/Orlando, FL (Vocus) May 30, 2009 -- Cancer researchers from the National Surgical Adjuvant Breast and Bowel Project (NSABP) and Allegheny General Hospital (AGH) in Pittsburgh will report today at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando that use of the drug bevacizumab (Avastin) in combination with standard chemotherapy was not effective in prolonging disease-free survival (DFS) in patients with stage II and stage III colon cancer when given for one year. There is promise that using Avastin for periods longer than one year will lead to improved efficacy.

Approved by the U.S. Food and Drug Administration in 2004 for the treatment of metastatic colorectal cancer and subsequently for the treatment of breast and lung cancer, Avastin is a medicine that interferes with the growth of cancer cells by inhibiting the formation of new blood vessels in cancerous tumors.

According to Norman Wolmark, M.D., principal investigator and chairman of both the NSABP and AGH’s Department of Human Oncology, the study being presented at ASCO is the first to explore use of Avastin in the adjuvant setting for patients with earlier stages of colon cancer.

Between September, 2004 and October, 2005, 2,710 patients with stage II and stage III colon cancer were randomized in the prosp
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine news :

1. Surveyed Experts Indicate That the Combination of Sutent and Taxol Has Advantages Over the Combination of Avastin and Taxol in the Treatment of Metastatic Triple-Negative Breast Cancer
2. Avastin effective at delaying brain tumor progression in recurrent disease
3. Use of Avastin and Erbitux in the Adjuvant Setting and Launches of Emerging Agents Will Drive the Colorectal Cancer Drug Market to $7.8 Billion in 2017
4. Surveyed Oncologists Indicate that Avastin has Advantages over Temodar/Temodal in Increasing Overall Survival of High-Grade Glioma
5. Avastin and Other Emerging Agents Will Drive the Glioma Drug Market to More Than $1.8 Billion in 2017
6. Genentech/Roche/Chugais Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017
7. Avastin Added to Chemo Helps Women With Advanced Breast Cancer
8. Avastin Added to Chemo Helps Women With Advanced Cancer
9. Off-Label Avastin Use for Wet Macular Degeneration
10. FDA OKs Avastin for Advanced Breast Cancer
11. In Combination With FOLFOX4, the Effect of Erbitux and Avastin On Survival Rates Will Drive Prescription Decisions in the Treatment of Stage III Colon Cancer

Post Your Comments:

Avastin Unsuccessful as Adjuvant Therapy in Setting of Stage II and III Colon Cancer but May Be Effective if Given for Longe...( Cancer resea...),Health